Clinical Trial Update: GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of GP96 heat shock protein-peptide complex vaccine for recurrent or progressive glioma completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain and Central Nervous System Tumors
• Glioma

Drugs mentioned

• gp96 heat shock protein peptide complex vaccine (gp96 heat shock protein peptide complex)

Snippet

Sponsor: University of California, San Francisco | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-05-13